CPhI Worldwide-organized by UBM (part of Informa PLC)- released part two of its annual report, evaluating the effects of regulatory diligence, trade agreements, and IP rights over the next five years. Two annual report experts believe that IPRs and trade agreements and regulator divergence could potentially have profound global impacts.
The full findings of the CPhI Annual Report include 12 in-depth expert contributions as well as the CPhI Manufacturing and Bio leagues tables, which will evaluate the relative reputations of each major pharma country.
To view the report, click here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.